GLP-1 receptor
Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes
Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.
Enhancing GI Tolerability of GLP-1 Receptor Agonists: A Path to Improved Therapeutic Outcomes
GLP-1 receptor agonists, gastrointestinal tolerability, therapeutic strategies, diabetes management, obesity treatment